Physician profile

Katherine E Ericson

Nurse Practitioner · Sioux Falls, SD

NPI 1346723830

$12,735.12

in general payments reported to CMS, 2019-2025

36 companies · $2,787 in 2025

The $2,787 reported for 2025 was more than what 96% of Nurse Practitioner providers received nationally (typical 2025 total: $174).

See the full distribution for Nurse Practitioner

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$7,218.29
Travel and Lodging$1,023.66
Education$100.70

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Zoll Respicardia, INC. $1,666.94 2023 Remede System
Astrazeneca Pharmaceuticals LP $1,419.10 2021-2025 Tezspire, Airsupra, Fasenra
Mylan Specialty L.P. $993.23 2021-2024 Yupelri
Harmony Biosciences LLC $983.24 2021-2025 Wakix
Glaxosmithkline, LLC. $960.94 2021-2025 Trelegy Ellipta, Nucala, Arexvy
Grifols USA, LLC $811.64 2021-2025 Prolastin-C Liquid
Abbvie INC. $671.27 2021-2025
Takeda Pharmaceuticals U.S.A., INC. $575.47 2021-2025 Glassia
Boehringer Ingelheim Pharmaceuticals, INC. $519.57 2021-2025 Ofev, Jascayd
Electromed, INC. $466.50 2022-2025 Smartvest
Viatris Specialty LLC $415.70 2025 Yupelri
Neurocrine Biosciences, INC. $364.27 2024-2025 Ingrezza
Daiichi Sankyo INC. $354.58 2021-2024 Injectafer
Baxter Healthcare $286.83 2022-2025 Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System, Hillrom - Monarch Airway Clearance System
Philips North America LLC $285.47 2022-2025 Vest Therapy Und, (O58) Sleep Respiratory Care Und, (Ak6) Vest Therapy
Show all 36 companies
CompanyGeneral paymentsYearsTop products
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $283.54 2021-2025 Xifaxan
Insmed, INC. $269.54 2024-2025 Arikayce, Brinsupri
United Therapeutics Corporation $237.68 2021-2024 Tyvaso
Avadel Cns Pharmaceuticals, LLC $223.49 2023-2025 Lumryz
Biohaven Pharmaceuticals, INC. $196.13 2021
Amgen INC. $124.42 2021-2025 Tezspire
Regeneron Healthcare Solutions, INC. $110.52 2022-2025 Dupixent
Biohaven Pharmaceutical Holding Company LTD. $76.09 2022
Bayer Healthcare Pharmaceuticals INC. $59.20 2022-2024
Astellas Pharma US INC $50.55 2022-2024 Veozah
Actelion Pharmaceuticals US, INC. $49.14 2022-2024 Opsumit, Uptravi
Verona Pharma, INC. $46.52 2025 Ohtuvayre
Jazz Pharmaceuticals INC. $41.16 2021-2022
Genzyme Corporation $37.86 2024
Pfizer INC. $34.59 2023
Almatica Pharma LLC $33.51 2022
Itamar Medical INC $20.50 2021
Teva Pharmaceuticals USA, INC. $19.92 2022
Advanced Respiratory, INC $16.99 2021
Idorsia Pharmaceuticals US INC $15.09 2023 Quviviq
Axsome Therapeutics, INC. $13.93 2025 Sunosi

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Katherine E Ericson

$12,735.12

in general payments reported 2019-2025

Years
2021-2025
Top company
Zoll Respicardia, INC.
Context
The $2,787 reported for 2025 was more than what 96% of Nurse Practitioner providers received nationally (typical 2025 total: $174).

https://glasscript.com/doctor/10536363/katherine-e-ericson

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.